71°

Site search

Open user controls
- Log In Using Your Account
  Log In
  
  Don't have an account? Sign Up Today

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Home
- Contact Us
- Subscribe
News
Sports
Features
Classifieds
Obituaries
Subscribe
E-Edition
Readers' Choice

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Akebia Therapeutics, Inc. - Common Stock (NQ:AKBA)

0.7229 +0.0209 (+2.98%)

Delayed Quote Updated: 10:21 AM EDT, Oct 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Akebia Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Akebia Therapeutics (NASDAQ:AKBA) Slides 24.6% Despite Q2 Earnings Beat ↗

August 05, 2026

Via Chartmill

Akebia Therapeutics Q2 Earnings Call Highlights ↗

August 05, 2026

Akebia Therapeutics (NASDAQ:AKBA) reported second-quarter revenue growth for its Vafseo anemia treatment while highlighting an interim clinical result from the VOICE study and progress across its...

Via MarketBeat

Topics Earnings

Akebia Therapeutics Sees Vafseo Uptake Rising as Access and Pipeline Milestones Near ↗

June 04, 2026

Akebia Therapeutics (NASDAQ:AKBA) outlined its commercial priorities for Vafseo, the expected evolution of reimbursement after the TDAPA period and several renal-disease pipeline programs during a...

Via MarketBeat

Topics Intellectual Property

Akebia (AKBA) Q1 2026 Earnings Transcript ↗

May 08, 2026

Akebia (AKBA) Q1 2026 Earnings Transcript

Via The Motley Fool

Akebia Therapeutics Inc (NASDAQ:AKBA) Reports Q4 Revenue Beat and 49% Annual Growth Amid Mixed Market Reaction ↗

February 26, 2026

Via Chartmill

Earnings Scheduled For November 10, 2025 ↗

November 10, 2025

Via Benzinga

An Overview of Akebia Therapeutics's Earnings ↗

November 07, 2025

Via Benzinga

Akebia (AKBA) Q4 2025 Earnings Call Transcript ↗

February 26, 2026

Akebia (AKBA) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

AKBA Shares Rise On Clinical Pipeline Optimism As Anemia Drug Gains Traction ↗

February 26, 2026

The company said on Thursday that it now expects its mid-stage trial of AKB-097 in rare kidney diseases to start in the second half of 2026, with initial data expected in 2027.

Via Stocktwits

Q32 Bio Stock Soars On Selling Experimental Drug To Akeba For Up To $592M ↗

December 01, 2025

The company said that the sale extends its cash runway into the second half of 2027.

Via Stocktwits

12 Health Care Stocks Moving In Monday's Intraday Session ↗

November 10, 2025

Via Benzinga

Akebia Therapeutics Stock Slumps After FDA Meeting Ends Without Path Forward for Vafseo Label Expansion ↗

October 29, 2025

Via Stocktwits

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

Earnings Preview For Akebia Therapeutics ↗

August 06, 2025

Via Benzinga

Top 3 Health Care Stocks Which Could Rescue Your Portfolio In November ↗

November 04, 2025

Via Benzinga

FDA Pushback Prompts Akebia To Drop Broad Label Pursuit For Kidney Disease Drug ↗

October 29, 2025

Akebia shares decline after the company ends plans for its VALOR trial, citing FDA feedback and high costs tied to expanding Vafseo's label.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

October 29, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

October 29, 2025

Via Benzinga

Earnings Scheduled For May 8, 2025 ↗

May 08, 2025

Via Benzinga

Insights Ahead: Akebia Therapeutics's Quarterly Earnings ↗

May 07, 2025

Via Benzinga

Mondelez International, Stride, Varonis Systems And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

October 29, 2025

Via Benzinga

Why Teradyne Shares Are Trading Higher By More Than 20%; Here Are 20 Stocks Moving Premarket ↗

October 29, 2025

Via Benzinga

Wondering what's happening in today's after-hours session? ↗

October 28, 2025

As the regular session of the US market on Tuesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

October 28, 2025

Via Benzinga

Akebia (AKBA) Q2 Revenue Jumps 43% ↗

August 07, 2025

Via The Motley Fool

9 Health Care Stocks Whale Activity In Today's Session ↗

June 04, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

May 08, 2025

Via Benzinga

Here are the top movers in Thursday's session. ↗

March 20, 2025

Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.

Via Chartmill

Top movers in Thursday's session ↗

March 20, 2025

Intrigued by the market activity in the middle of the day on Thursday? Uncover the key winners and losers of today's session in our insightful analysis.

Via Chartmill

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

March 20, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard Times

Services

Contact Us
Subscription Services
Promote Your Event
Site Forms
Search

ricentral.com
187 Main Street
Wakefield, RI 02879
Phone: 401-789-9744
Email: news@ricentral.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Log In Using Your Account

Akebia Therapeutics, Inc. - Common Stock (NQ:AKBA)

All News about Akebia Therapeutics, Inc. - Common Stock

Sections

Services